Chromocell Therapeutics (CHRO) Short Interest Ratio & Short Volume

Short interest is the volume of Chromocell Therapeutics shares that have been sold short but have not yet been closed out or covered. As of June 15th, traders have sold 76,900 shares of CHRO short. 8.70% of Chromocell Therapeutics' shares are currently sold short. Learn More on Chromocell Therapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 8.70% of Chromocell Therapeutics' floating shares are currently sold short.

Chromocell Therapeutics saw a decline in short interest in June. As of June 15th, there was short interest totaling 76,900 shares, a decline of 38.9% from the previous total of 125,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Chromocell Therapeutics currently has issued a total of 6,485,000 shares. Some of Chromocell Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Chromocell Therapeutics currently has a public float of 883,900 shares.

8.70% of Chromocell Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Chromocell Therapeutics: Hyperion DeFi, Inc. (4.05%), RenovoRx, Inc. (0.38%), Iterum Therapeutics PLC (3.59%), Clearside Biomedical, Inc. (2.29%), Dyadic International Inc. (0.24%), CASI Pharmaceuticals Inc. (8.18%), Kezar Life Sciences, Inc. (11.77%), Akari Therapeutics PLC (0.24%), Dare Bioscience, Inc. (1.97%), Trinity Biotech PLC (11.43%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($69.26 billion), Invesco QQQ ($25.22 billion), iShares Russell 2000 ETF ($20.33 billion), iShares 20+ Year Treasury Bond ETF ($9.99 billion), Strategy Inc ($9.12 billion), Canadian Natural Resources Limited ($6.73 billion), SPDR S&P Biotech ETF ($6.52 billion), Invesco S&P 500 Equal Weight ETF ($5.60 billion), Financial Select Sector SPDR Fund ($4.64 billion), and iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.59 billion). View all of the most shorted stocks.

Short selling CHRO is an investing strategy that aims to generate trading profit from Chromocell Therapeutics as its price is falling. CHRO shares are trading up $0.08 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Chromocell Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CHRO, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CHRO, twice per month. The most recent reporting period available is June, 15 2025.